SCHEMBL3513022

SCHEMBL3513022

CC(C)(NC(=O)c1c(O)c2cccnc2n(Cc2ccc(C(F)(F)F)cc2)c1=O)C(=O)O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 8/20 0.66
CNR1 P21554 3/20 0.54
PTGDR2 Q9Y5Y4 1/20 0.53
EGLN1 Q9GZT9 4/20 0.49
EGLN2 Q96KS0 2/20 0.49
EGLN3 Q9H6Z9 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.45
HIF1A Q16665 1/20 0.45
MAPT P10636 1/20 0.45
THRB P10828 1/20 0.45
HPGD P15428 1/20 0.45
CYSLTR2 Q9NS75 1/20 0.43
HDAC1 Q13547 1/20 0.42
HDAC11 Q96DB2 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
EP300 Q09472 1/20 0.42
CREBBP Q92793 1/20 0.42
KAT2A Q92830 1/20 0.42
KAT2B Q92831 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24937532 0.91 CNR2 (0.80) CNR2CNR1HIF1AMAPT
SCHEMBL3512731 0.85 EGLN1 (0.65) CNR2CNR1PTGDR2EGLN1EGLN2
SCHEMBL3513909 0.85 CNR2 (0.58) CNR2CNR1PTGDR2EGLN1EGLN2
SCHEMBL3512393 0.85 CNR2 (0.58) CNR2CNR1PTGDR2EGLN1EGLN2
SCHEMBL3514102 0.83 CNR2 (0.56) CNR2CNR1PTGDR2EGLN1EGLN2
SCHEMBL3516806 0.83 CNR2 (0.56) CNR2CNR1PTGDR2EGLN1EGLN2
SCHEMBL3513720 0.82 CNR2 (0.57) CNR2CNR1PTGDR2EGLN1EGLN2
SCHEMBL3512643 0.81 CNR2 (0.54) CNR2CNR1PTGDR2EGLN1EGLN2
SCHEMBL4566579 0.81 CNR2 (0.54) CNR2CNR1PTGDR2EGLN1EGLN2
SCHEMBL3512358 0.81 CNR2 (0.54) CNR2CNR1PTGDR2EGLN1EGLN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100056563-A1 NOVEL 1.8-NAPHTHYRIDINE COMPOUNDS MERCK SHARP & DOHME CORP. 2010-03-04 US claimed
CN-101663037-A Novel 1,8-naphthyridine compounds MERCK & CO INC 2010-03-03 CN claimed
US-20100056563-A1 NOVEL 1.8-NAPHTHYRIDINE COMPOUNDS MERCK SHARP & DOHME CORP. 2010-03-04 US disclosed
US-20100056563-A1 NOVEL 1.8-NAPHTHYRIDINE COMPOUNDS MERCK SHARP & DOHME CORP. 2010-03-04 US disclosed
US-20100056563-A1 NOVEL 1.8-NAPHTHYRIDINE COMPOUNDS MERCK SHARP & DOHME CORP. 2010-03-04 US disclosed
CN-101663037-A Novel 1,8-naphthyridine compounds MERCK & CO INC 2010-03-03 CN disclosed
WO-2008130527-A1 NOVEL 1,8-NAPHTHYRIDINE COMPOUNDS MERCK & CO., INC. (US) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056563-A1 NOVEL 1.8-NAPHTHYRIDINE COMPOUNDS HIF1AN, HIF1A, EGLN2 CNR2 2485/4885CNR1 1567/4885PTGDR2 1858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.